Status:
TERMINATED
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Triple Negative Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
Brief Summary
The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.
Detailed Description
This is a phase II, single center, prospective, single arm clinical trial. A lot of in vitro and in vivo study demonstrate that deferoxamine can increase anti-tumor effect. The objective of the study ...
Eligibility Criteria
Inclusion
- Has measurable metastatic triple-negative breast cancer, with at least 1 measurable lesion per RECIST criteria.
- Fail second-line or above anti-tumor treatment
- Evaluation is stable disease with a trend of progression.
- Minimum life expectancy 16 weeks
- Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis
- ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks
- Normal organ function.
- Has signed a Patient Informed Consent Form.
Exclusion
- Eastern Cooperative Oncology Group (ECOG) score of ≥ 2
- Patients with severe liver and kidney insufficiency
- Deferoxamine Ingredients allergy
- With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment
- Inability or unwillingness to comply with study procedures, including inability to take regular oral medication
- Researchers consider it is not suitable for participation.
Key Trial Info
Start Date :
March 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 21 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05300958
Start Date
March 21 2022
End Date
July 21 2025
Last Update
July 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060